AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
CryptoAlerta — análise de criptomoedas e mercado em tempo real